Just 12.5 percent of the world has been inoculated against Covid-19. To protect every country from the pandemic, regardless of economic level, there are many approaches global leaders could take. But they have to act fast. In this state of planetary emergency, should pharmaceutical companies that make vaccines be forced to break their patents? Is that the best or fastest way to get lower-income countries to catch up with vaccination rates? Weighing the pros and cons of a vaccine intellectual property waiver with Jane Coaston this week is Rachel Silverman, a policy fellow at the Center for Global Development, and Tahir Amin, a co-founder and co-executive director of I-MAK, the Initiative for Medicines, Access & Knowledge.
Mentioned in this episode:
(A full transcript of the episode will be available midday on the Times website.)
Thoughts? Email us at email@example.com or leave us a voice mail message at (347) 915-4324. We want to hear what you’re arguing about with your family, your friends and your frenemies. (We may use excerpts from your message in a future episode.)
By leaving us a message, you are agreeing to be governed by our reader submission terms and agreeing that we may use and allow others to use your name, voice and message.
“The Argument” is produced by Phoebe Lett, Elisa Gutierrez and Vishakha Darbha and edited by Alison Bruzek and Paula Szuchman; fact-checking by Kate Sinclair; music and sound design by Isaac Jones; audience strategy by Shannon Busta.